What are Recombinant hepatitis B vaccine with adjuvant drugs?

Recombinant hepatitis B vaccine with adjuvant drugs are pharmacologic agents that share a common mechanism (typically targeting Hepatitis B surface antigen (HBsAg); TLR4 (via MPL adjuvant)). 0 are currently marketed, with 3 more in clinical development.

Recombinant hepatitis B vaccine with adjuvant

0 marketed 3 in Phase 3

This page covers all Recombinant hepatitis B vaccine with adjuvant drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Hepatitis B surface antigen (HBsAg); TLR4 (via MPL adjuvant), Hepatitis B surface antigen (HBsAg).

Targets

Hepatitis B surface antigen (HBsAg); TLR4 (via MPL adjuvant) · Hepatitis B surface antigen (HBsAg)

Phase 3 pipeline (3)

HBV-MPL vaccine · GlaxoSmithKline · Immunology / Infectious Disease
HBV-MPL vaccine stimulates immune response against hepatitis B virus by combining hepatitis B surface antigen with MPL (monophosphoryl lipid A), an adjuvant that enhances T-cell and B-cell activation.
Fendrix vaccine · Henogen · Immunology / Infectious Disease
Fendrix is a recombinant hepatitis B vaccine that stimulates immune response against hepatitis B surface antigen using an AS04 adjuvant system to enhance immunogenicity.
HBV-MPL vaccine (208129) · GlaxoSmithKline · Immunology / Infectious Disease
HBV-MPL vaccine stimulates immune response against hepatitis B virus by combining hepatitis B surface antigen with MPL (monophosphoryl lipid A), a toll-like receptor 4 agonist adjuvant.